Zoledronic acid for hip fracture during initial hospitalization
Main finding · Cumulative all-cause mortalityResult — go to the resultHazard ratio 0.62 95% CI 0.49–0.78Authors' conclusion
IP-ZA, administered during the initial hospitalization for hip fracture, was associated with lower all-cause-mortality and risk of radiologically confirmed subsequent new vertebral fractures
Study context
- Population
- Patients hospitalized for hip fracture; 71.7% female, 92.1% White, mean age 80.9 yearsmatched cohort
- Participants
- 652 vs 1,926
- Exposure
- Inpatient zoledronic acid vs no inpatient zoledronic acid (IP-ZA) during index hospitalization
- IP-ZAn = 652
- Untreatedn = 1,926reference
- Outcome
- All-cause mortality
- Follow-up
- 24-month follow-up
Methodological detailstarget trial emulation using real-world data, propensity-matched
- Target trial emulation using real-world data
- Propensity-matched
Main finding
Cumulative all-cause mortality · 24 months
Hazard ratio
0.62
95% CI 0.49–0.78
P < 0.001
By group
IP-ZAvs Untreated
HR 0.62 (95% CI 0.49–0.78); P < 0.001
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | IP-ZA | Untreated | HR (95% CI) | P value | |
|---|---|---|---|---|---|
| All-cause mortality, single-dose ZA subgroup · 24 monthsSingle dosevs Untreated | 0.70 (0.55–0.89) | P = 0.003 | |||
| Radiologically confirmed cumulative subsequent new vertebral fractures | 2.0% | 5.4% | 0.40 (0.22–0.71) | P = 0.001 | |
| New vertebral fractures, single-dose subgroupSingle dosevs Untreated | — not stated in the abstract | 5.4% | 0.44 (0.24–0.82) | P = 0.008 | |
| 0.20.5125Hazard ratio (log scale) |
— not stated in the abstract
- All-cause mortality, single-dose ZA subgroup: Single dose 13.3%
- All-cause mortality, single-dose ZA subgroup: 585 (89.7%) of IP-ZA received only a single dose
- New vertebral fractures, single-dose subgroup: Single dose 1.9%
Original publication
Zoledronic acid for hip fracture during initial hospitalization. J Bone Miner Res. Published 2 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →